1454928-68-7

Basic information

• Product Name: C₂₈H₃₄N₆O
• CAS NO: 1454928-68-7
• Molecular Weight: 470.618
• Mol File: 1454928-68-7.mol

Chemical Properties

• CAS DataBase Reference: C₂₈H₃₄N₆O(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₈H₃₄N₆O(1454928-68-7)
• EPA Substance Registry System: C₂₈H₃₄N₆O(1454928-68-7)

Safety Data

• Hazardous Substances Data: 1454928-68-7(Hazardous Substances Data)

Upstream product

• 1454928-56-3 1-(4-tert-butylbenzyl)-4-ethyl-3-(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1H-1.2.4-triazol-5(4H)-one 
• 56621-91-1 5-amino-2-bromopyrimidine 
• 1454928-51-8 3-(3-(4-bromophenyl)propyl)-1-(4-tert-butylbenzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one 
• 1454928-46-1 3-(3-(4-bromophenyl)propyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one 
• 1454928-85-8 C₁₃H₁₈BrN₃O₂ 
• 1454928-45-0 4-(4-bromophenyl)butanehydrazide 
• 35656-89-4 4-(4-bromophenyl)butanoic acid 

Downstream Products

• 1454926-58-9 N-(2-(4-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)phenyl)pyrimidin-5-yl)benzenesulfonamide 

Relevant articles and documents

Identification of the first potent, selective and bioavailable PPARα antagonist

The discovery and SAR of a novel series of potent and selective PPARα antagonists are herein described. Exploration of replacements for the labile acyl sulfonamide linker led to a biaryl sulfonamide series of which compound 33 proved to be suitable for further profiling in vivo. Compound 33 demonstrated excellent potency, selectivity against other nuclear hormone receptors, and good pharmacokinetics in mouse.

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.